1. |
Mula M. Epilepsy and psychiatric comorbidities: drug selection. Current Treatment Options in Neurology, 2017, 19(12): 44.
|
2. |
Tellez-Zenteno JF, Patten SB, Jetté N, et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia, 2007, 48(12): 2336-2344.
|
3. |
Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand, 2004, 110(4): 207-220.
|
4. |
Munger Clary HM. Anxiety and epilepsy: what neurologists and epileptologists should know. Curr Neurol Neurosci Rep, 2014, 14(5): 445.
|
5. |
Engel J, Jr. Evolution of concepts in epilepsy surgery. Epileptic Disord, 2019, 21(5): 391-409.
|
6. |
Fisher PL, Noble AJ. Anxiety and depression in people with epilepsy: The contribution of metacognitive beliefs. Seizure, 2017, 50: 153-159.
|
7. |
Cavanna AE, Cavanna S, Bertero L, et al. Depression in women with epilepsy: clinical and neurobiological aspects. Funct Neurol, 2009, 24(2): 83-87.
|
8. |
Economou M, Madianos M, Peppou LE, et al. Suicidal ideation and reported suicide attempts in Greece during the economic crisis. World Psychiatry, 2013, 12(1): 53-59.
|
9. |
Lacey CJ, Salzberg MR, D'Souza WJ. Risk factors for depression in community-treated epilepsy: systematic review. Epilepsy Behav, 2015, 43: 1-7.
|
10. |
Kanner AM, Schachter SC, Barry JJ, et al. Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav, 2012, 24(2): 156-168.
|
11. |
Naess S, Eriksen J, Tambs K. Psychological well-being of people with epilepsy in Norway. Epilepsy Behav, 2007, 11(3): 310-315.
|
12. |
Mensah SA, Beavis JM, Thapar AK, et al. The presence and clinical implications of depression in a community population of adults with epilepsy. Epilepsy Behav, 2006, 8(1): 213-219.
|
13. |
Asadi-Pooya AA, Kanemoto K, Kwon OY, et al. Depression in people with epilepsy: How much do Asian colleagues acknowledge it? Seizure, 2018, 57: 45-49.
|
14. |
Rocha L, Alonso-Vanegas M, Martínez-Juárez IE, et al. GABAergic alterations in neocortex of patients with pharmacoresistant temporal lobe epilepsy can explain the comorbidity of anxiety and depression: the potential impact of clinical factors. Front Cell Neurosci, 2014, 8: 442.
|
15. |
Kang JQ, Barnes G. A common susceptibility factor of both autism and epilepsy: functional deficiency of GABA A receptors. J Autism Dev Disord, 2013, 43(1): 68-79.
|
16. |
Conway CR, Udaiyar A, Schachter SC. Neurostimulation for depression in epilepsy. Epilepsy Behav, 2018, 88s: 25-32.
|
17. |
Butler T, Harvey P, Cardozo L, et al. Epilepsy, depression, and growth hormone. Epilepsy Behav, 2019, 94: 297-300.
|
18. |
Vezzani A, French J, Bartfai T, et al. The role of inflammation in epilepsy. Nat Rev Neurol, 2011, 7(1): 31-40.
|
19. |
Levinson AJ, Fitzgerald PB, Favalli G, et al. Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry, 2010, 67(5): 458-464.
|
20. |
Singh T, Goel RK. Epilepsy associated depression: an update on current scenario, suggested mechanisms, and opportunities. Neurochem Res, 2021, 46(6): 1305-1321.
|
21. |
Colmers PLW, Maguire J. Network Dysfunction in Comorbid Psychiatric Illnesses and Epilepsy. Epilepsy Curr, 2020, 20(4): 205-210.
|
22. |
Hultman R, Ulrich K, Sachs BD, et al. Brain-wide electrical spatiotemporal dynamics encode depression vulnerability. Cell, 2018, 173(1): 166-180.e114.
|
23. |
Gil F, Padilla N, Soria-Pastor S, et al. Beyond the epileptic focus: functional epileptic networks in focal epilepsy. Cereb Cortex, 2020, 30(4): 2338-2357.
|
24. |
Zarcone D, Corbetta S. Shared mechanisms of epilepsy, migraine and affective disorders. Neurological Sciences, 2017, 38(S1): 73-76.
|
25. |
Yuan F, Jia R, Gao Q, et al. Early predictors of drug-resistant epilepsy development after convulsive status epilepticus. European Neurology, 2018, 79(5-6): 325-332.
|
26. |
Błaszczyk B, Czuczwar SJ. Epilepsy coexisting with depression. Pharmacol Rep, 2016, 68(5): 1084-1092.
|
27. |
Lambert MV, Robertson MM. Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia, 1999, 40(Suppl 10): 21-47.
|
28. |
Kanner AM, Palac S. Depression in epilepsy: a common but often unrecognized comorbid malady. Epilepsy Behav, 2000, 1(1): 37-51.
|
29. |
Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia, 2014, 55(4): 475-482.
|
30. |
Gill SJ, Lukmanji S, Fiest KM, et al. Depression screening tools in persons with epilepsy: a systematic review of validated tools. Epilepsia, 2017, 58(5): 695-705.
|
31. |
McPherson A, Martin CR. A narrative review of the Beck Depression Inventory (BDI) and implications for its use in an alcohol-dependent population. J Psychiatr Ment Health Nurs, 2010, 17(1): 19-30.
|
32. |
Zapata Barco AM, Restrepo-Martínez M, Restrepo D. Depression in People with Epilepsy. What is the Connection? Rev Colomb Psiquiatr (Engl Ed), 2020, 49(1): 53-61.
|
33. |
Solmi M, Veronese N, Zaninotto L, et al. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr, 2016, 21(5): 403-418.
|
34. |
Fountoulakis KN, Karavelas V, Moysidou S, et al. Efficacy of add-on pregabalin in the treatment of patients with generalized anxiety disorder and unipolar major depression with an early nonresponse to escitalopram: a double-blind placebo-controlled study. Pharmacopsychiatry, 2019, 52(4): 193-202.
|
35. |
Elger CE, Johnston SA, Hoppe C. Diagnosing and treating depression in epilepsy. Seizure, 2017, 44: 184-193.
|
36. |
Thomé-Souza MS, Kuczynski E, Valente KD. Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy Behav, 2007, 10(3): 417-425.
|
37. |
Gilliam FG, Black KJ, Carter J, et al. A Trial of sertraline or cognitive behavior therapy for depression in epilepsy. Ann Neurol, 2019, 86(4): 552-560.
|
38. |
Hovorka J, Herman E, Nemcová II. Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy Behav, 2000, 1(6): 444-447.
|
39. |
Abou-Khalil BW. Update on antiepileptic drugs 2019. Continuum (Minneap Minn), 2019, 25(2): 508-536.
|
40. |
Chentouf A. Depression in patients with epilepsy: screening, diagnosis and management. Tunis Med, 2021, 99(5): 518-524.
|
41. |
Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res, 2016, 106: 72-86.
|
42. |
Neugebauer R, Paik M, Hauser WA, et al. Stressful life events and seizure frequency in patients with epilepsy. Epilepsia, 1994, 35(2): 336-343.
|
43. |
de Tisi J, Bell GS, Peacock JL, et al. The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet, 2011, 378(9800): 1388-1395.
|
44. |
Michaelis R, Tang V, Goldstein LH, et al. Psychological treatments for adults and children with epilepsy: Evidence-based recommendations by the International League Against Epilepsy Psychology Task Force. Epilepsia, 2018, 59(7): 1282-1302.
|
45. |
Spindler P, Bohlmann K, Straub HB, et al. Effects of vagus nerve stimulation on symptoms of depression in patients with difficult-to-treat epilepsy. Seizure, 2019, 69: 77-79.
|
46. |
McDonald TJW, Cervenka MC. Ketogenic diets for adult neurological disorders. Neurotherapeutics, 2018, 15(4): 1018-1031.
|
47. |
Koh S, Dupuis N, Auvin S. Ketogenic diet and neuroinflammation. Epilepsy Res, 2020, 167: 106454.
|